Novel Drug Delivery Systems of Chinese Medicine for the Treatment of Inflammatory Bowel Disease

Overview

Journal Chin Med

Publisher Biomed Central

Specialty Biomedical Engineering

Date 2019 Jun 26

PMID 31236131

Citations 22

Authors

Caifang Gao

Lijuan Liu

Yangyang Zhou

Zhaoxiang Bian

Shengpeng Wang

Yitao Wang

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn's disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non-steroidal anti-inflammatory drugs, glucocorticoids, and immunosuppressive agents are used for the treatment of IBD, while their clinical application is severely limited due to unwanted side effects. Chinese medicine (CM) is appealing more and more attention and investigation for the treatment of IBD owing to the potent anti-inflammation pharmacological efficacy and high acceptance by patients. In recent years, novel drug delivery systems are introduced apace to encapsulate CM and many CM-derived active constituents in order to improve solubility, stability and targeting ability. In this review, advanced drug delivery systems developed in the past and present to deliver CM for the treatment of IBD are summarized and future directions are discussed.

Citing Articles

New insights of engineering plant exosome-like nanovesicles as a nanoplatform for therapeutics and drug delivery.

Shinge S, Xiao Y, Xia J, Liang Y, Duan L Extracell Vesicles Circ Nucl Acids. 2024; 3(2):150-162.

PMID: 39698444 PMC: 11648482. DOI: 10.20517/evcna.2021.25.

Optimal traditional Chinese medicine formulas in treating ulcerative colitis: Choose one or take it all?.

Zeng Y, Zhang J, Yang J World J Clin Cases. 2024; 12(32):6570-6574.

PMID: 39554899 PMC: 11438634. DOI: 10.12998/wjcc.v12.i32.6570.

Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6/IL-6R axis.

Liu C, Gong Q, Liu W, Zhao Y, Yan X, Yang T J Transl Med. 2024; 22(1):963.

PMID: 39448992 PMC: 11515557. DOI: 10.1186/s12967-024-05682-x.

Calycosin prevents NLRP3-induced gut fibrosis by regulating IL-33/ST2 axis.

Liao X, Xie H, Yu S Heliyon. 2024; 10(9):e30240.

PMID: 38726105 PMC: 11078877. DOI: 10.1016/j.heliyon.2024.e30240.

Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS-stimulated macrophages via inactivating MAPK signaling pathway.

Huang H, Tang S, Zhou Y, Cai Y Immun Inflamm Dis. 2024; 12(5):e1077.

PMID: 38722267 PMC: 11080961. DOI: 10.1002/iid3.1077.

References

Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H . Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol Ther. 2013; 21(7):1345-57. PMC: 3702113. DOI: 10.1038/mt.2013.64. View

Wang S, Chen R, Zhong Z, Shi Z, Chen M, Wang Y . Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells. Am J Chin Med. 2014; 42(5):1279-300. DOI: 10.1142/S0192415X14500803. View

Ulbrich W, Lamprecht A . Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J R Soc Interface. 2009; 7 Suppl 1:S55-66. PMC: 2843985. DOI: 10.1098/rsif.2009.0285.focus. View

Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos G . Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis. 2014; 9(1):86-106. DOI: 10.1093/ecco-jcc/jju007. View

Guo B, Bian Z, Qiu H, Wang Y, Wang Y . Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease. Ann N Y Acad Sci. 2017; 1401(1):37-48. DOI: 10.1111/nyas.13414. View

Blanco-Garcia E, Otero-Espinar F, Blanco-Mendez J, Leiro-Vidal J, Luzardo-Alvarez A . Development and characterization of anti-inflammatory activity of curcumin-loaded biodegradable microspheres with potential use in intestinal inflammatory disorders. Int J Pharm. 2017; 518(1-2):86-104. DOI: 10.1016/j.ijpharm.2016.12.057. View

Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E . Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol. 2002; 37(4):444-9. DOI: 10.1080/003655202317316088. View

Yen C, Chen Y, Wu M, Wang C, Wu Y . Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide. Int J Nanomedicine. 2018; 13:669-680. PMC: 5798547. DOI: 10.2147/IJN.S154824. View

Zhou S, Zhang B, Liu X, Teng Z, Huan M, Yang T . A new natural angelica polysaccharide based colon-specific drug delivery system. J Pharm Sci. 2009; 98(12):4756-68. DOI: 10.1002/jps.21790. View

10.

Schaible A, Traber H, Temml V, Noha S, Filosa R, Peduto A . Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin. Biochem Pharmacol. 2013; 86(4):476-86. DOI: 10.1016/j.bcp.2013.04.015. View

11.

Wang S, Zhang J, Chen M, Wang Y . Delivering flavonoids into solid tumors using nanotechnologies. Expert Opin Drug Deliv. 2013; 10(10):1411-28. DOI: 10.1517/17425247.2013.807795. View

12.

Pinto J . Site-specific drug delivery systems within the gastro-intestinal tract: from the mouth to the colon. Int J Pharm. 2010; 395(1-2):44-52. DOI: 10.1016/j.ijpharm.2010.05.003. View

13.

Thakral S, Thakral N, Majumdar D . Eudragit: a technology evaluation. Expert Opin Drug Deliv. 2012; 10(1):131-49. DOI: 10.1517/17425247.2013.736962. View

14.

Bassotti G, Gaburri M . Manometric investigation of high-amplitude propagated contractile activity of the human colon. Am J Physiol. 1988; 255(5 Pt 1):G660-4. DOI: 10.1152/ajpgi.1988.255.5.G660. View

15.

Abdin A . Targeting sphingosine kinase 1 (SphK1) and apoptosis by colon-specific delivery formula of resveratrol in treatment of experimental ulcerative colitis in rats. Eur J Pharmacol. 2013; 718(1-3):145-53. DOI: 10.1016/j.ejphar.2013.08.040. View

16.

Loddo I, Romano C . Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis. Front Immunol. 2015; 6:551. PMC: 4629465. DOI: 10.3389/fimmu.2015.00551. View

17.

Zhang F, Li Y, Xu F, Chu Y, Zhao W . Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. J Altern Complement Med. 2013; 19(10):838-42. DOI: 10.1089/acm.2012.0296. View

18.

Park J, Pramanick S, Park D, Yeo J, Lee J, Lee H . Therapeutic-Gas-Responsive Hydrogel. Adv Mater. 2017; 29(44). DOI: 10.1002/adma.201702859. View

19.

Sokol H, Seksik P, Cosnes J . Complications and surgery in the inflammatory bowel diseases biological era. Curr Opin Gastroenterol. 2014; 30(4):378-84. DOI: 10.1097/MOG.0000000000000078. View

20.

Raj P, Raj R, Kaul A, Mishra A, Ram A . Biodistribution and targeting potential assessment of mucoadhesive chitosan nanoparticles designed for ulcerative colitis scintigraphy. RSC Adv. 2022; 8(37):20809-20821. PMC: 9080856. DOI: 10.1039/c8ra01898g. View